InvAscent partially exits Symbiotec Pharmalab via IPO, pre-IPO share sales
Bitget2026/09/21 18:14- InvAscent advised Rosewood Investment on a partial exit from Symbiotec Pharmalab via pre-IPO share sales, followed by the IPO.
- The partnership began with an INR 3.44 billion investment in December 2018; the fund retained a meaningful stake post-listing.
- Symbiotec manufactures corticosteroid, steroid-hormone APIs; it has expanded into CDMO services and complex injectables during the holding period.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
Crypto prices
More
